Last reviewed · How we verify
NCT03739229
Reactogenicity, Safety and Immunogenicity of a LAIV А/17/Hong Kong/2017/75108 H7N9 Influenza Vaccine
Phase 1 trial testing Placebo in Vaccine Adverse Reaction in 40 participants. Status unknown.
3 June 2019
Quick facts
| Lead sponsor | Research Institute of Influenza, Russia |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | prevention |
| Enrollment | 40 |
| Start date | 3 December 2018 |
| Primary completion | 3 June 2019 |
| Estimated completion | 3 July 2019 |
Drugs / interventions tested
- Placebo
- H7N9 LAIV — full drug profile →
Conditions studied
- Vaccine Adverse Reaction — all drugs for Vaccine Adverse Reaction →
Sponsor
Research Institute of Influenza, Russia
Who can join
Adults 18 to 49, any sex, with Vaccine Adverse Reaction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single center phase I, double-blind placebo-controlled study to assess reactogenicity, safety and immunogenicity of a live monovalent A/17/Hong Kong/2017/75108 (H7N9) influenza vaccine in healthy male and female adults, 18 through 49 years of age.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Pandemic preparedness through vaccine development for avian influenza viruses.
Cargnin Faccin F, Perez DR. · · 2024 · cited 34× · PMID 38807261 · DOI 10.1080/21645515.2024.2347019 -
A Phase 1 Randomized Placebo-Controlled Study to Assess the Safety, Immunogenicity and Genetic Stability of a New Potential Pandemic H7N9 Live Attenuated Influenza Vaccine in Healthy Adults.
Kiseleva I, Isakova-Sivak I, Stukova M, Erofeeva M, et al · · 2020 · cited 7× · PMID 32532097 · DOI 10.3390/vaccines8020296 -
Antigenic Characterization of Neuraminidase of Influenza A/H7N9 Viruses Isolated in Different Years.
Desheva Y, Losev I, Petkova N, Kudar P, et al · · 2022 · cited 2× · PMID 36145348 · DOI 10.3390/ph15091127
Verify or expand the search:
- PubMed search for NCT03739229
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Vaccine Adverse Reaction
Currently open trials in the same condition.
- NCT06180447 — Peri-conceptional or Pregnancy Exposure of Vaccination and the Risk of Adverse Pregnancy Outcomes · active not recruiting
- NCT05898464 — Immunogenicity and Safety of Recombinant Zoster Vaccine in People Living With HIV · Phase 4 · active not recruiting
- NCT06286488 — Effectiveness and Tolerability of Influenza Vaccine in Patients at Risk for Severe and Complicated Influenza · Phase 4 · active not recruiting
Other Research Institute of Influenza, Russia trials
Trials by the same sponsor.
- NCT06873282 — Phase 2 Study of the ТВ/Flu-05Е Tuberculosis Vaccine · Phase 2 · completed
- NCT06890429 — Phase 2 Study of the RSV/Flu-01E Vaccine Against Respiratory Syncytial Virus Infection in Older Adults · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03739229 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Research Institute of Influenza, Russia
- Last refreshed: 13 November 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03739229.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing